Top Cardiology CRO Providers – Contract Research Organization

When you’re in the market for a Cardiology CRO, it’s important to know what to look for. There are some common traits that distinguish a good Cardiology CRO from a bad one. These qualities include a strong scientific foundation, responsiveness, and operational rigor.

Cardiology CRO (Cardiology conversion rate optimization) is an effective way to increase the ROI of marketing campaigns. This practice-level strategy is particularly helpful for multi-location cardiology practices, as it helps them improve their lead-to-customer ratio. It also maximizes ad spend by eliminating unnecessary steps before a conversion.

Vial Cardiology CRO

Vial CRO is a full-service, international Cardiology CRO specializing in cardiovascular research. Based in Verona, Italy, the company has more than 50 years of experience in the field. Its services are flexible and customized to meet clients’ specific needs. From regulatory consulting services to full-service clinical trials, Vial CRO team is committed to providing the best possible service to its clients.

The Vial Cardiology CRO is an ISO-certified international firm with offices in Europe and North America. It specializes in cardiovascular clinical trials, including large pivotal trials and registry studies with large datasets. Cardiology CRO also has extensive experience in developing cardiovascular devices, including stents and drug-eluting stents.

A broad portfolio of services and a highly-experienced team of professionals help Vial CRO address your needs and ensure a successful clinical trial. Vial CRO can tailor its services to meet your specific needs and can even consult with you on overall development plans. A Vial CRO consultant can advise you on the most appropriate strategy for your research.

Most CROs provide a full spectrum of services, including clinical trial monitoring, data management, and medical writing. Others offer a range of preclinical services including materials characterization and analytical testing. Several providers also provide training. While most CROs are based in North America, a growing number are headquartered in Europe.

The Vial Cardiology CRO report covers more than 300 companies worldwide. It also provides an in-depth review of the industry, including analysis of their size, year of establishment, and scope of operation. Further, the report provides an overview of regulatory bodies worldwide and provides analysis of key stakeholders in the field.

Cardialysis

Cardialysis is a leading academic research organization (CRO) in the cardiovascular field. The organization has extensive experience in conducting clinical trials for both pharmaceutical and biotechnology companies. Cardialysis’s global network of clinical research associates, each with more than five years of experience, ensures timely and quality data collection and submission. The company’s expert clinical research associates are also accustomed to working with diverse sites in the cardiovascular field.

Cardialysis and Sticares InterACT, both CROs based in the Netherlands, recently announced a strategic collaboration to provide drug development services for cardiovascular and metabolic disease research. Both companies share a common history in academia and have a strong connection with key opinion leaders in the field. This allows them to provide expert drug development services beyond those offered by the average CRO.

Cardialysis is a leading cardiovascular CRO that offers full clinical research services, including cardiac core laboratory services. The company was founded in 1983 and has a reputation for opinion-leader expertise, a broad academic network, and a deep understanding of the cardiovascular field. The company also has extensive experience in phase II and CE-marked clinical trials.

Cardialysis’s capabilities and Sticares InterACT’s extensive network of sites in 26 countries make them complementary. Both companies excel in core laboratory techniques, web-based clinical event adjudication, data management, medical monitoring, and statistical analysis. In addition to their complementary strengths, both companies have deep expertise in electrophysiology, data management, and clinical trial site management.

Cardialysis has developed strong relationships with the Erasmus Medical Center in Rotterdam to advance their research capabilities. The two companies have collaborated on various studies, including cardiovascular imaging, and have developed close ties to each other. Cardialysis has also successfully implemented optical coherence tomography, which uses near-infrared light to produce three-dimensional images.

IQVIA Cardiology CRO

IQVIA is one of the largest contract research organizations in the world. It specializes in cardiovascular drug development and trials, and its clinical experts leverage high-powered information and technology assets to expedite site activation and optimize patient recruitment. IQVIA’s CenterWatch survey is conducted biannually and includes more than 60,000 respondents. Its team of cardiovascular experts is comprised of medical researchers, industry experts, and other health care professionals.

IQVIA, formerly Quintiles, provides consulting and biopharmaceutical development services for phase I to IV clinical trials. Founded in 1982, IQVIA has five offices in 100 countries and more than 58,000 employees worldwide. IQVIA’s revenue in 2018 was $10.4 billion. The company was formed from a merger between Inc Research and Quintiles. IQVIA Cardiology CRO is based in Durham, North Carolina.

The Clinical Research Associate (CRA) performs site evaluations, conducts initiation visits, and reviews and assesses the progress of clinical investigations in accordance with Good Clinical Practices. This position works closely with the Clinical Trial Manager. The Senior CRA performs site evaluations to assess the ability of a site to conduct the clinical trial.

Jen Ohme, M.D., is an experienced Cardiology Clinical Research Organization with more than 30 years of experience. Jen has held various leadership and business development roles at global contract research organizations. She has more than 16 years of experience in healthcare technology and has been in clinical research for more than 15 years. She has a Bachelor of Arts degree from the University of Minnesota and an MBA from Augsburg College.

Read also: Neurology CRO – Contract Research Organization Services

Worldwide Clinical Trials

As a full-service CRO for cardiovascular research, Worldwide has a long and diverse track record of success. Its expertise spans hundreds of thousands of patients around the world, and its technology allows study sponsors to monitor patient compliance and intervene if necessary. In addition, Worldwide is backed by an engaged team of experts dedicated to the success of your project.

The vascular field encompasses a diverse array of medical conditions, from coronary artery disease to cerebrovascular disease, which means a unique set of challenges. To ensure a successful trial, you need access to experts and participants, from various regions and countries. Worldwide Clinical Trials is the ideal solution for this problem.

Whether you’re conducting a pivotal study or a prospective observational study, you need to know how to choose the right method. Consider what your patients will receive and how many patients you’ll need to study. For example, if you need more than 30 patients, a large academic center with the ability to deliver these numbers will be most appropriate.

The key to successful cardiovascular clinical trials is to partner with an experienced CRO. For this reason, IQVIA offers unmatched experience in cardiovascular trials and new approaches driven by data and analytics. By combining these capabilities, Worldwide is able to deliver the highest quality cardiovascular clinical trials. Our experts can handle both large and small trials, and can work with you to design the most effective trial for your needs.

Worldwide Clinical Trials joins the Science 37 CRO Certified network. This network supports CROs in the delivery of decentralized clinical studies by providing commercial support and access to training. Its mission is to improve patient outcomes and access to clinical trials worldwide. Our certification and accreditation provide a unique platform that enhances our ability to deliver clinical trials.

Karen Hill

Karen Hill, Senior Vice President of Project Management in Worldwide’s Cardiometabolic Franchise, has over 25 years of experience in cardiovascular research. She oversees projects ranging from Phase II-IV clinical trials to cardiometabolic outcome mega-studies and observational studies. As Vice President, Karen manages a global team of CRAs and project managers. Her background spans clinical trials in all phases, including Phase I, II and III, and a wide range of pharmacological, biomedical, and biotechnology companies.

Karen has extensive experience in regulatory affairs for IVDs and has worked as a regulatory affairs manager for Vascutek Ltd, a Terumo company specializing in vascular implants. She has also served as a clinical study manager at Axis Shield Diagnostics Ltd and is a member of the Organization for Professionals in Regulatory Affairs. She holds a BSc in Biochemistry and Pharmacology from the University of Strathclyde.

Novotech

Novotech Cardiology CRO provides a range of clinical trial services to pharmaceutical companies in the area of cardiovascular disease. It has expertise in atrial fibrillation and a number of other therapeutic areas, and works closely with Principal Investigators to identify appropriate trial sites. In addition, Novotech develops strong relationships with trial sites and maintains close communication with them.

The company has recently attracted investors from Mercury Capital, which has a 30% stake with an option to buy up to 50%. Founded by former Goldman Sachs managing director Clark Perkins, Mercury Capital invests in companies with a market value of $30 million to $1 billion. The firm is excited by the growth opportunities in Asia and Australia, and the outsourcing trend in the pharmaceutical industry.

A key focus area for Novotech is the Asia-Pacific region. With 11 regional offices in the region, it has an extensive portfolio of clinical trial services. These include feasibility assessments, regulatory filings, safety services, central lab services, and report writing to ICH standards. The company is a strong partner for biotech companies seeking global regulatory services.

As a biotechnology CRO, Novotech has a proven track record of success. It has conducted more than 1,000 Phase I – IV clinical trials for biotechnology companies in a variety of therapeutic areas, including cardiovascular disease. It also has deep expertise in respiratory and allergy disorders, neurology, oncology, metabolic disorders, and inflammatory and autoimmune diseases.

The partnership between Novotech and Prospection will help speed up the process of developing a new medicine. It will also help accelerate the patient recruitment process, which is one of the biggest hurdles in developing new medicines. The companies will work together to identify study sites with the greatest recruitment potential.